Pharmacy Technician Pulse

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

pharmaphorum

NOVEMBER 19, 2020

Because Roche has never applied for Avastin to be used in wet AMD, clinics in the US have had to choose between the peace of mind offered by the regulatory process and Lucentis’ higher price tag, or the unapproved off-label formulation of Avastin at a lower price.

FDA

FDA Labelling

A history of Pfizer

pharmaphorum

DECEMBER 2, 2020

This caused Pfizer to change its tactics, and instead the company ended up signing a deal with GSK to combine the two companies’ consumer health businesses and form a joint venture with combined annual sales of $12.7 For all the latest Pfizer news follow pharmaphorum’s Pfizer tag.

Compounding

Compounding Vaccines Pharmaceutical Companies Pharmaceutical Companies

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

A history of Pfizer

Stay Connected